| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 243.68M | — |
| Operating expense | — | — |
| Net income | -152.22M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, 2CL.F returned +71.5% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +9.6% |
| 1 year | +71.5% |
| 5 years | +72.7% |
| All-time high | €69.85 (Aug 2026) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in 2CL.F would be worth today ›No. BridgeBio Pharma, Inc. has not paid a dividend in the past 12 months.
BridgeBio Pharma, Inc. is part of the Healthcare sector.
BridgeBio Pharma, Inc. has a market cap of 13.64B EUR, based on the latest quote.
BridgeBio Pharma, Inc. is expected to report earnings around Oct 28, 2026. That date is an estimate and has not been confirmed by the company.
